BioCentury
ARTICLE | Emerging Company Profile

QR: Power of positivity

QR Pharma rescuing deprioritized Alzheimer's compounds

May 30, 2011 7:00 AM UTC

QR Pharma Inc. has in-licensed a pair of compounds for cognitive impairment and Alzheimer's disease it believes have suffered from neglect rather than a lack of efficacy or safety.

The more advanced of the two compounds is Posiphen, a positive enantiomer of phenserine that has completed a Phase I/II trial for mild cognitive impairment...